ASH 2019: Dr. Jennifer Brown on Using Ibrutini... - CLL Support
ASH 2019: Dr. Jennifer Brown on Using Ibrutinib After Progressing on Venetoclax for Ibrutinib-Naïve Patients with CLL
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax
ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with...
ASH 2019: U-MRD by subgroup (ibrutinib+venetoclax) CAPTIVATE trial
This is how we achieve personalized, precision medicine.
73% of patients achieved U-MRD4 in BM...
Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD
In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over...
ASH 2016: Dr. Mato on real world data on ibrutinib
Hi,
This week I'm posting an interview that I had with Dr. Anthony Mato from U Penn when we talked...
New Clinical Trial of Ibrutinib + Venetoclax for people relapsing on Ibrutinib
Yesterday I started a new clinical trial at UCSD for people that have relapsed on Ibrutinib. I had...
Related Posts
Long-term effects of ibrutinib on blood pressure in patients with CLL- Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL
After you stop with ibrutinib - does Sll-CLL come back?- Late breaking CLL abstract at ASH 2018 (FCR vs IR for untreated younger patients)
- Three Year Anniversary on Ibrutinib for my CLL
